|
|
|
||||||||||
|
Updated May 2009 Postdoctoral positions in new cancer treatment approaches Original positions filled -- continuing openings for qualified candidates This NCI-funded research concerns a new evolved highly effective enzyme (ChrR6; also called Y6) for prodrug therapy (see publications), and a new reductive prodrug, CNOB, which is not only effective, but has the property that its reduced active form is highly fluorescent. ChrR6/CNOB is a superior treatment for cancer in mice, and permits imaging of CNOB activation and barriers to its distribution in live animal and within the microenvironment of solide tumors. Thus, countermeasures to penetration barriers in the tumors can be tested withoht animal sacrifice. The openings are for current research on: using noninvasive bioimaging (NBI) to improve the reach of the active drug within the tumors; enhancing the imaging technology; and exploring superior ways for specific tumor targeting of the gene/enzyme/ drug. The incoming postdocs will interact with a multidisciplinary team of Stanford scientists involved in cell biology/ biochemistry; NBI (at Molecular Imaging Program at Stanford); specific nanoparticle-based tumor targeting; pharmacokinetics and biostatistics. Candidates with a Ph. D. degree with demonstrated productivity in one or more of these areas are invited to apply with CV and three recommendation letters to: Professor A. C. Matin at: a.matin@stanford,edu. Salaries and benefits are competitive; an equal opportunity employer. Opportunities also in other areas of our research.
|
|||||||||||
|
|||||||||||
